



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



SX-682

Cat. No.:	HY-119339
CAS No.:	1648843-04-2
Molecular Formula:	C ₁₉ H ₁₄ BF ₄ N ₃ O ₄ S
Molecular Weight:	467.2
Target:	CXCR
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (535.10 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	2.1404 mL	10.7021 mL	21.4041 mL	
		5 mM	0.4281 mL	2.1404 mL	4.2808 mL	
	10 mM	0.2140 mL	1.0702 mL	2.1404 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 15% Cremophor EL >> 85% Saline Solubility: 11.76 mg/mL (25.17 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.45 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity ^[1] .	
IC ₅₀ & Target	CXCR1	CXCR2
In Vivo	SX-682 (50 mg/kg; orally; twice a day on a Monday through Friday) has Meager to moderate effects as single agents on CRPC progression was observed, yet combination with ICB produced strong efficacy^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

Animal Model:	C57BL/6NTac-Tyr ^{tm1Arte} female mice ^[2]
Dosage:	50 mg/kg
Administration:	Orally; twice a day on a Monday through Friday
Result:	Has Meager to moderate effects on CRPC progression.

CUSTOMER VALIDATION

- Hepatology. 2022 Feb 2.
- J Exp Clin Cancer Res. 2024 Mar 19;43(1):86.
- Cell Death Dis. 2021 Nov 1;12(11):1038.
- Infect Immun. 2023 Mar 7;e0001423.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Sun L, et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 2019 Apr 4;4(7).
- [2]. Lu X, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017 Mar 30;543(7647):728-732.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA